Experienced Health Sciences Professional | Scientific Projects Manager | Medical and Science Communicator
Are we entering a new era for the treatment of (at least a subtype) of #parkinsondisease. There is room for optimism, as well as caution till we reasonably grasp the effects of GLP-1 agonists on pathogenic processes driving neuronal dysfunction in PD. For a long time, there was a dogma on peptic ulcer disease that it is caused by excessive acid in stomach. Now, we know that the condition can be treated in vast majority by antibiotics to eradicate H. pylori. I am afraid that we face similar dogmas in PD research (ie. role of excessive synuclein accumulation thought as the cause). We shared our reflections on this topic https://lnkd.in/dEgNDtdd
The full results of the phase 2 clinical trial of lixisenatide have now been published. This Cure Parkinson’s co-funded trial has reported positive results, indicating that the treatment may slow the progression of motor symptoms. Find out more: https://buff.ly/4aBOZN2 Van Andel Institute #CureParkinsons #Parkinsons #ParkinsonsResearch #ChangeTheFuture